Peripancreatic Lymph Nodes: Anatomy, Function, and Pathology

Peripancreatic lymph nodes are the clusters of immune tissue surrounding the pancreas, and they serve as both the organ’s first line of immunological defense and the most common route through which pancreatic cancer spreads. Their anatomy is surprisingly complex: rather than forming a single ring, they organize into distinct chains that follow the major arteries feeding the pancreas, with drainage patterns that shift depending on which part of the organ is involved. That complexity matters enormously in surgery, staging, and diagnosis, where misunderstanding which nodes drain which segment of the pancreas can change outcomes.

How Peripancreatic Lymph Nodes Are Arranged

The pancreas sits deep in the upper abdomen, draped across the spine and nestled among major blood vessels. Its lymph nodes are not a single group but a constellation of stations named for the arteries and structures they surround. Anatomic dissection studies have identified three major lymphatic pathways on the front surface of the pancreatic head alone: an upper pathway associated with the common hepatic artery group, and middle and lower routes tied to the superior mesenteric artery group. All three converge on a node sitting just to the right of where the celiac trunk and superior mesenteric artery branch off the aorta.¹ Behind that convergence point, a separate terminal node collects lymph from the back surface of the head.

The left half of the pancreas, meaning the body and tail, follows a different scheme. Two pathways carry lymph from these segments: one runs along the splenic artery and vein, and the other accompanies the inferior pancreatic artery. Both ultimately drain to a node on the left side of the celiac trunk and superior mesenteric artery origins.¹ This left-right split in drainage is clinically meaningful: a tumor in the pancreatic tail sends its metastatic cells along a completely different nodal highway than one in the head.

The Japanese Pancreas Society has formalized this geography into a numbering system of roughly 28 lymph node stations, spanning from the nodes around the stomach’s cardia (stations 1 and 2) all the way down to para-aortic nodes below the renal veins (station 16b2). Detailed cadaveric imaging confirms how these stations relate to one another in three dimensions, with nodes arrayed around the celiac trunk, hepatoduodenal ligament, splenic hilum, superior mesenteric artery, and along the aorta itself.²

Drainage Patterns Depend on Where in the Pancreas You Look

One of the more important findings in peripancreatic lymphatic anatomy is that the head of the pancreas itself is not a uniform territory. Dye-injection studies have shown that the uncinate process (the hook-like projection behind the mesenteric vessels) drains primarily along the superior mesenteric route to reach the right inter-celio-mesenteric node and then the supra- and infrarenal node groups. The front-upper segment of the head, by contrast, drains via a gastroduodenal route that crosses the upper border of the pancreas. And the back-upper segment frequently sends lymph along the common bile duct and hepatic artery, staining the pericholedochal and hepatic pedicle nodes.³

This segmental drainage has real implications for surgery. A study examining lymph node involvement by tumor location found that for head tumors, certain nodes that are classified as “regional” by staging systems actually had zero involvement when the tumor sat in the uncinate process, while mesocolon nodes (not classified as regional) were frequently positive in head tumors overall.⁴ For tail tumors, nodes along the celiac axis and common hepatic artery had zero involvement despite being designated as regional. The mismatch between formal staging categories and actual metastatic patterns suggests that a one-size-fits-all lymph node template may over-dissect some areas while under-sampling others.

Immune Surveillance and the Gut Connection

Beyond serving as relay stations for cancer spread, peripancreatic lymph nodes are active immune organs. They filter antigens draining from the pancreas and mount adaptive immune responses, including responses that sometimes go wrong. Research into type 1 diabetes has found that a specific subset of immune cells, regulatory T cells, is reduced in peripancreatic lymph nodes of people who go on to develop the disease, even before clinical onset. This reduction appears before symptoms and may reflect an early breakdown in the immune system’s ability to protect pancreatic insulin-producing cells from autoimmune attack.⁵

Perhaps more surprising is the discovery that peripancreatic lymph nodes are shared. The pancreas, liver, and gut co-drain into some of the same nodes, meaning immune signals from the intestines can directly influence what happens in nodes that also serve the pancreas. Research in animal models has shown that this shared drainage offers a mechanism by which a gastrointestinal infection could lower the threshold for autoimmunity in the pancreas, without the pancreas itself ever being infected.⁶ This co-drainage adds a layer of complexity to how we think about organ-specific immune disease.

Lymph Node Involvement in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, spreads to peripancreatic lymph nodes with striking frequency. In one study of pancreatic head cancers, peripancreatic lymph node metastasis was found in nearly nine out of ten patients who had any positive nodes at all.⁷ The pattern of spread matters for prognosis: among patients with limited nodal disease (N1), metastasis specifically to the pericholedochal or superior mesenteric artery nodes carried a worse outcome than spread confined to other peripancreatic stations.

There is also a stepwise geographic logic to spread: para-aortic node metastasis, which is considered distant disease, was seldom seen in patients whose peripancreatic nodes (stations 13, 14, and 17) were clean.⁸ This suggests that cancer generally spreads outward through the local nodal network before reaching distant sites. But it does not always play by those rules. A substantial number of PDAC patients with negative regional lymph nodes still develop distant metastases, apparently skipping the nodal step entirely.⁹ The unpredictability of this “jumping” behavior is one of the reasons pancreatic cancer remains so difficult to manage.

Counting Nodes, Ratios, and Why the Numbers Matter

Staging systems classify lymph node involvement as either absent or present, with newer editions also stratifying by the number of positive nodes. But crude counts have limitations. A large population-based analysis found that even among patients with no cancer in any lymph node, the number of nodes actually examined by the pathologist predicted survival: those who had twelve or more nodes examined lived a median of 23 months, compared with 16 months when fewer than twelve were checked.¹⁰ This does not mean that removing more nodes cures cancer. It likely reflects a combination of more thorough surgery, more meticulous pathological examination, and the statistical reality that checking more nodes makes it less likely you will miss a positive one.

For patients who do have positive nodes, the lymph node ratio (the proportion of examined nodes that contain cancer) has emerged as a powerful prognostic tool. In the same analysis, rising lymph node ratios correlated with progressively shorter survival: patients with ratios above 0.4 survived a median of ten months, compared with fifteen months for those with ratios of 0.2 or less.¹⁰ Multiple studies have confirmed that the lymph node ratio performs at least as well as formal staging categories in predicting outcomes, and some analyses suggest it outperforms them.¹¹¹²

One complication: neoadjuvant therapy (chemotherapy or radiation given before surgery) tends to obliterate some lymph nodes, lowering the total count the pathologist can examine and improving the ratio even if residual cancer cells remain. Studies of patients who received the most intensive preoperative regimens found median node counts of ten, down from twenty-two in patients who went straight to surgery, with corresponding improvements in the ratio.¹³ This raises questions about whether the minimum node counts traditionally recommended for adequate staging still apply after aggressive preoperative treatment.

The Extended Lymphadenectomy Debate

Given that more involved nodes predict worse outcomes, a natural question is whether surgeons should remove more nodes. The idea behind extended lymphadenectomy is to sweep wider, clearing para-aortic and other distant stations in addition to the standard peripancreatic template. Early single-center trials hinted that node-positive patients might benefit: one prospective multicenter study found that node-positive patients who received an extended dissection had survival curves matching those of node-negative patients.¹⁴ That subgroup analysis, however, was not preplanned, and the overall survival comparison between standard and extended groups showed no difference.

Subsequent meta-analyses have confirmed the negative result. A systematic review and meta-analysis found no significant difference in overall survival or disease-free survival between extended and standard lymphadenectomy. Extended dissections did retrieve more positive lymph nodes on average but did not translate that into better outcomes. Operative time increased substantially, and quality of life in the first year after surgery was worse in the extended group.¹⁵¹⁶ The current consensus is that extended lymphadenectomy for PDAC is not recommended as standard practice.

When Enlarged Nodes Are Not Cancer

Enlarged peripancreatic lymph nodes on imaging do not always mean malignancy, and distinguishing benign enlargement from metastatic disease is one of the trickier problems in abdominal radiology. Autoimmune pancreatitis (AIP), an inflammatory condition driven by IgG4-producing immune cells, causes peripancreatic and peribiliary nodes to enlarge and show follicular hyperplasia.¹⁷ IgG4-positive plasma cells infiltrate not just the pancreas itself but also peripancreatic tissue, bile ducts, and the lymph nodes in every case examined in one series.¹⁸ AIP can form a mass that looks indistinguishable from pancreatic cancer on a CT scan, making tissue sampling essential before committing a patient to major surgery.

Tuberculosis involving peripancreatic lymph nodes is another mimic. Even in people with healthy immune systems, TB can present as a pancreatic head mass with enlarged surrounding nodes, leading to an initial diagnosis of cancer. Case reports describe patients taken to surgery for suspected malignancy only to find granulomatous inflammation consistent with TB.¹⁹ The incidence of primary peripancreatic lymph node TB has been rising in developed countries, and endoscopic ultrasound-guided biopsy has proven useful for catching these cases before unnecessary operations.²⁰ Rare entities like Castleman disease can also present as a hypervascular pancreatic head mass with multiple enlarged abdominal and retroperitoneal lymph nodes, confirmed only after surgical resection and pathological examination.

Imaging and Biopsy Challenges

Detecting whether peripancreatic lymph nodes harbor cancer before surgery remains difficult. Standard imaging with CT and MRI performs modestly. One study evaluating various criteria for node positivity in pancreatic head cancer found that using size alone (the most intuitive criterion) had a sensitivity of only about 44%, meaning more than half of truly positive nodes were missed. Adding criteria like irregular borders or uneven signal intensity did not dramatically improve matters; specificity went up but sensitivity stayed low.²¹ The fundamental problem is that small metastatic deposits can sit in normal-sized nodes, and reactive inflammatory changes can make benign nodes look suspicious.

Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) improves the picture. By placing an ultrasound probe in the stomach or duodenum, clinicians can visualize peripancreatic nodes in real time and sample them with a needle. Reported sensitivity for pancreatic and peripancreatic lesions runs around 82%, with specificity near 89%.²² Fine needle biopsy (EUS-FNB), which retrieves a core of tissue rather than just loose cells, has shown even better specificity for lymph node evaluation in comparative analyses, particularly for abdominal nodes and peri-hepatic lesions.²³ Tissue sampling remains the gold standard when imaging is ambiguous.

Peripancreatic Nodes in Neuroendocrine Tumors

Pancreatic neuroendocrine tumors (PNETs) are a biologically distinct family of tumors that behave very differently from PDAC. They tend to grow more slowly, and the significance of lymph node spread is more nuanced. In one combined cohort analysis, overall survival at ten years was roughly 80% regardless of whether patients had no metastases or only lymph node metastases.²⁴ However, patients with positive nodes developed liver metastases significantly faster, and the number of involved nodes predicted both the speed of liver spread and, with longer follow-up, disease-related death.

Lymph node metastasis in PNETs is not random. Larger tumors (over 1.5 cm), tumors in the pancreatic head, those with high proliferative activity, and those with lymphovascular invasion are all significantly more likely to have nodal spread.²⁵ Median disease-free survival roughly tripled in node-negative patients compared with node-positive ones in that same series (about 14.5 years versus 4.5 years). After adjusting for tumor size and grade, having positive nodes still carried a meaningfully increased risk of disease-related death.²⁶ These findings support performing a regional lymph node dissection during PNET surgery, even though the survival timeline is measured in years rather than the months that characterize PDAC.

Fluorescence-Guided Lymph Node Mapping

One of the more promising recent developments in peripancreatic surgery is the use of fluorescent dyes, particularly indocyanine green (ICG), to map lymphatic drainage in real time during an operation. When injected near the tumor, ICG travels through lymphatic channels and lights up under near-infrared imaging, allowing surgeons to see which nodes are draining the tumor bed. Early experience has confirmed that fluorescence imaging can delineate peripancreatic lymphatic drainage and highlight specific fluorescent nodes during anatomical lymphadenectomy.²⁷

Case reports of ICG-guided lymphadenectomy during laparoscopic distal pancreatectomy for neuroendocrine tumors have demonstrated that the technique can illuminate peripancreatic lymph nodes at specific stations in real time, serving as a visual adjunct to the standard anatomic dissection.²⁸ Whether this translates into retrieving more clinically relevant nodes or improving survival has not been established in prospective trials. The technology is still in its early clinical phase for pancreatic surgery, but it represents a shift toward personalized surgical mapping rather than relying solely on predetermined anatomical templates.

The Lymphatic Microenvironment and Cancer Invasion

Beyond simply counting which nodes contain metastatic cells, researchers are increasingly interested in how pancreatic cancer remodels the lymphatic vessels themselves to facilitate spread. Histological analysis has shown that cancer cells invade lymphatic channels preferentially at the edges of pancreatic lobules, in areas where new lymphatic vessel growth is occurring. The invasion process involves the cancer cells pushing inward against the lymphatic vessel lining, a process described as invagination of the lymphatic endothelium.²⁹

Multi-omics profiling of tumors with lymphovascular invasion has revealed a deeply immunosuppressive local environment: exhausted killer T cells, macrophages skewed toward a tumor-promoting state, and highly active cancer-associated fibroblasts. Within the tumor cells themselves, upregulation of a surface protein called BST2 appears to drive enhanced metastatic potential through a signaling cascade that promotes the epithelial-to-mesenchymal transition, the molecular program that enables cancer cells to detach and migrate.³⁰ Understanding these mechanisms is opening new avenues for therapies that might block cancer cells from entering lymphatic channels in the first place, rather than relying solely on surgical removal of nodes after the fact.